Table 1.

Potential IL-17–related treatments for OA

Drug name	Target	Research platform	Effect	Refs.
RA10-6	IL-17/IL-6	Mice	Suppression of OA synovial inflammation	[110]
Krocina™	Th17/IL-17	Humans (clinical trial)	Suppression of OA synovial inflammation	[111]
Resveratrol	IL-17/NF-κB	Rats	Repair of OA soft tissue damage	[111]
Platelet-rich- plasma	IL-17	Rats	Improvement of joint function, pain and inflammatory	[112,113,114]
Baccharis	IL-17	Mice	Suppression of OA immune inflammatory	[115]
Pioglitazone	IL-17/NF-κB	Human myeloid cells and tissues	Inhibition of mRNA expression of inflammatory mediators	[116]
1,25-Vit D3	Th17	Dendritic cells	Inhibition of pro-inflammatory cytokine	[117]
Dexamethas-one	Th17	Dendritic cells	Inhibition of pro-inflammatory cytokine	[118]
Apremilast	IL-17	ATDC5 chondrocytes	Inhibition of inflammatory factors, cellular senescence, ROS	[76]
Salidroside	CD4+/IL-17	Rats	Regulates inflammation and immune response	[118]